Service optimisation in interstitial lung disease (ILD)

Boehringer Ingelheim is committed to supporting the NHS to bring about improvements in patient care and healthcare services. 

We have a long history of innovation in respiratory medicine, including progressive pulmonary fibrosis and interstitial lung diseases. 

Bringing ILD experts together

We convened a group of experts to discuss the current service provision for ILD and what needs to improve. 

The resulting white paper outlines ways to shape policy and provides key service recommendations for improving how ILD services are provided across the NHS to improve both patient care and patient outcomes.

The white paper outlines how respiratory professionals and healthcare leaders can help to: 

• Address variation and inequalities in ILD service provision across England

• Effectively shape policy and recommend services to optimise awareness, diagnosis and care

• Drive ILD service change to benefit patient care and outcomes

If you are involved with NHS policy or are a respiratory healthcare professional and would like a copy of the white paper, please email communications.bra@boehringer-ingelheim.com.

The initial concept, funding and facilitation of the expert meeting was provided by Boehringer Ingelheim UK Ltd. The scope, content and final wording in the white paper has been generated and agreed by all named authors.